What type of study is this?

This is a Quantitative Study study.

September 17, 2025Open Access

A Novel Tumor-Penetrating Phosphorescent Nanoagent for Hypoxia-Activated NIR-II Bioimaging and Type-I PDT-Triggered Ferroptosis

View Full Paper

Ask AI

Bookmark

The novel phosphorescent nanoagent significantly improves tumor specificity with a 5-fold higher tumor-to-normal tissue ratio.
Hypoxia-activated NIR-II phosphorescence coupled with type-I PDT promotes effective ferroptosis, inhibiting tumor growth.
Intersystem crossing properties of the organometallic complex facilitate hypoxia-activated bioimaging and therapy simultaneously.
Proteomic analysis reveals the involvement of ferroptosis and apoptosis pathways in the therapeutic efficacy of the nanoagent.

No takes yet. Share an insight, caveat, or question.

Novel phosphorescent nanoagent boosts hypoxia-activated NIR-II imaging and improves tumor specificity, suggesting enhanced PDT applications.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Novel phosphorescent nanoagent boosts hypoxia-activated NIR-II imaging and improves tumor specificity, suggesting enhanced PDT applications.